Safety and Immunogenicity of Recombinant RSV Vaccine (CHO Cell) in Healthy Subjects Aged 18 Years and Above

NCT06642558 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

522

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

BIOLOGICAL: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(low dose)
BIOLOGICAL: Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)(high dose)
BIOLOGICAL: Placebo (Saline solution)

Sponsor

MAXVAX Biotechnology Limited Liability Company

Collaborators

[object Object]